Cheryl R. Blanchard - 15 Mar 2024 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
President, CEO, Director, Director
Signature
/s/ Cheryl R. Blanchard
Issuer symbol
ANIK
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4
Filing time
19 Mar 2024, 17:16:20 UTC
Previous filing
12 Mar 2024
Next filing
07 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Award $0 +75,395 $0.000000 75,395 15 Mar 2024 Common Stock 75,395 $0.000000 Direct F1
transaction ANIK Stock Option (Right to Buy) Award $0 +182,699 $0.000000 182,699 15 Mar 2024 Common Stock 182,699 $27.98 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
F2 Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
F3 The premium priced stock options vest in three equal annual installments beginning on March 15, 2025.